Fig. 3

Depletion of YB-1 results in resistance to platinum-based drugs. a Chemical structure of cisplatin. b Enriched genes identified from screens for cisplatin. FDR = 0.1 (blue dotted line). c Western blot validation of sgRNA-mediated depletion of YB-1 in HAP1. d YB-1 and beta-actin levels were analyzed by Western blot analysis in CRISPR-Cas9-targeted HeLa cells. e, f CRISPR-Cas9-targeted cells decreased their sensitivity to cisplatin in e HAP1 and f HeLa cells. g Chemical structure of carboplatin and oxaliplatin. h, i Depletion of YB-1 in HAP1 cells reduced their sensitivity to h carboplatin and i oxaliplatin